Campath, calcineurin inhibitor reduction, and chronic allograft nephropathy (the 3C Study) – results of a randomized controlled clinical trial
暂无分享,去创建一个
M. Landray | J. Emberson | C. Baigent | L. Blackwell | P. Harden | P. Friend | N. Staplin | R. Haynes | W. Herrington | P. Judge | B. Storey
[1] E. Akl,et al. CMV and BKPyV Infections in Renal Transplant Recipients Receiving an mTOR Inhibitor-Based Regimen Versus a CNI-Based Regimen: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials. , 2017, Clinical journal of the American Society of Nephrology : CJASN.
[2] F. Bemelman,et al. Early Conversion From Calcineurin Inhibitor‐ to Everolimus‐Based Therapy Following Kidney Transplantation: Results of the Randomized ELEVATE Trial , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[3] J. Chapman,et al. Calcineurin Inhibitor Nephrotoxicity Through the Lens of Longitudinal Histology: Comparison of Cyclosporine and Tacrolimus Eras , 2016, Transplantation.
[4] L. Rostaing,et al. Belatacept and Long-Term Outcomes in Kidney Transplantation. , 2016, The New England journal of medicine.
[5] G. Knoll,et al. Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data , 2014, BMJ : British Medical Journal.
[6] M. Landray,et al. Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial , 2014, The Lancet.
[7] G. Russ,et al. A Systematic Review of Conversion From Calcineurin Inhibitor to Mammalian Target of Rapamycin Inhibitors for Maintenance Immunosuppression in Kidney Transplant Recipients , 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[8] S. Fuggle,et al. Alemtuzumab and Sirolimus in Renal Transplantation: Six‐Year Results of a Single‐Arm Prospective Pilot Study , 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[9] C. Felipe,et al. Planned Randomized Conversion From Tacrolimus to Sirolimus‐Based Immunosuppressive Regimen in De Novo Kidney Transplant Recipients , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[10] M. Landray,et al. Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocol , 2013, Transplantation research.
[11] J. D. de Fijter,et al. Two-year randomized controlled prospective trial converting treatment of stable renal transplant recipients with cutaneous invasive squamous cell carcinomas to sirolimus. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] B. Nashan,et al. Wound Healing Complications and the Use of Mammalian Target of Rapamycin Inhibitors in Kidney Transplantation: A Critical Review of the Literature , 2012, Transplantation.
[13] E. Decullier,et al. Sirolimus and secondary skin-cancer prevention in kidney transplantation. , 2012, The New England journal of medicine.
[14] N. Mueller,et al. Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients. , 2012, Transplantation.
[15] R. Heilman,et al. Results of a Prospective Randomized Trial of Sirolimus Conversion in Kidney Transplant Recipients on Early Corticosteroid Withdrawal , 2011, Transplantation.
[16] A. Matas. Chronic Progressive Calcineurin Nephrotoxicity: An Overstated Concept , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[17] Thomas Becker,et al. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial , 2011, The Lancet.
[18] O. Pankewycz,et al. Conversion to low-dose tacrolimus or rapamycin 3 months after kidney transplantation: a prospective, protocol biopsy-guided study. , 2011, Transplantation proceedings.
[19] R. Collins,et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.
[20] P. Reinke,et al. Renal Function, Efficacy, and Safety of Sirolimus and Mycophenolate Mofetil After Short-Term Calcineurin Inhibitor-Based Quadruple Therapy in De Novo Renal Transplant Patients: One-Year Analysis of a Randomized Multicenter Trial , 2010, Transplantation.
[21] E. Thervet,et al. Efficacy on Renal Function of Early Conversion from Cyclosporine to Sirolimus 3 Months After Renal Transplantation: Concept Study , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[22] F. Schena,et al. Conversion From Calcineurin Inhibitors to Sirolimus Maintenance Therapy in Renal Allograft Recipients: 24-Month Efficacy and Safety Results From the CONVERT Trial , 2009, Transplantation.
[23] H. Ekberg. Calcineurin Inhibitor Sparing in Renal Transplantation , 2008, Transplantation.
[24] A. Lewington,et al. Poor Tolerance of Sirolimus in a Steroid Avoidance Regimen for Renal Transplantation , 2008, Transplantation.
[25] P. Halloran,et al. Reduced exposure to calcineurin inhibitors in renal transplantation. , 2007, The New England journal of medicine.
[26] N. Perico,et al. Sirolimus Versus Cyclosporine Therapy Increases Circulating Regulatory T Cells, But Does Not Protect Renal Transplant Patients Given Alemtuzumab Induction From Chronic Allograft Injury , 2007, Transplantation.
[27] G. Knoll,et al. Conversion From Calcineurin Inhibitors to Sirolimus for Chronic Renal Allograft Dysfunction: A Systematic Review of the Evidence , 2006, Transplantation.
[28] L. Rostaing,et al. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[29] M. Edey. Kaposi's sarcoma after renal transplantation. , 2005, The New England journal of medicine.
[30] D. Goldfarb,et al. The natural history of chronic allograft nephropathy. , 2005, The Journal of urology.
[31] J. Schold,et al. Long‐Term Renal Allograft Survival: Have we Made Significant Progress or is it Time to Rethink our Analytic and Therapeutic Strategies? , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[32] M. Arias,et al. Proteinuria: a new marker of long-term graft and patient survival in kidney transplantation. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[33] P. Friend,et al. Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients , 1998, The Lancet.
[34] M. Sayegh,et al. Kaposi's sarcoma after renal transplantation. , 1997, The New England journal of medicine.
[35] R. J. Hayes,et al. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. , 1995, JAMA.
[36] M. Pike,et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.
[37] P. Armitage,et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. , 1976, British Journal of Cancer.
[38] S. Pocock,et al. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. , 1975, Biometrics.
[39] F. Diekmann,et al. mTOR inhibitor-associated proteinuria in kidney transplant recipients. , 2012, Transplantation reviews.